Semaglutide and albumin

Albumin and persistence

Semaglutide resembles GLP-1, a hormone released from the gut after meals. Its chain has been altered to resist rapid breakdown, and an attached fatty part helps it bind albumin, a protein in blood. The semaglutide safety and clinical review provides the background to this long-acting medicine.

Natural GLP-1 disappears quickly, whereas semaglutide remains roughly a week. Albumin binding helps explain that persistence. I admire the reversible albumin attachment: a useful signal has been made to last long enough to investigate in a different way.

Semaglutide acts at GLP-1 receptors. It promotes insulin release when blood sugar is high, suppresses inappropriate glucagon release and slows food leaving the stomach. Insulin helps cells take up blood sugar; glucagon raises it. Approved semaglutide products include tablets and injections for particular indications, including type 2 diabetes and chronic weight management.

Appetite circuits in rodents

A study in mice and rats mapped several brain pathways involved in semaglutide-associated weight loss. The rodents ate less and changed food preferences, without a decrease in energy expenditure. The work traced access to regions of the hypothalamus and brainstem involved in appetite.

That is a striking reach for a molecule related to a gut hormone. It gives a biological explanation to investigate alongside the human appetite experience. The cardiovascular and kidney results below came from separate patient trials, each with its own population and outcomes.

STEP 1, SELECT and FLOW

STEP 1 enrolled 1,961 adults with overweight or obesity and without diabetes. At 68 weeks, mean body-weight change was −14.9% with semaglutide and −2.4% with placebo. These are group means from the trial, with individual responses varying around them.

SELECT followed 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide lowered the risk of a combined outcome comprising cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo.

In FLOW, 3,533 people had both type 2 diabetes and chronic kidney disease. Semaglutide lowered the risk of the combined outcome of kidney failure, a fall of at least 50% in estimated kidney filtration, or death from kidney or cardiovascular causes, compared with placebo.

I value the breadth of these patient outcomes. These trials asked about different forms of illness in different groups, so the achievement includes having measured those outcomes directly. The tirzepatide comparison answers another question about average weight change.

Digestive symptoms, gallbladder and eyes

The 2021 safety review describes mostly transient, mild-to-moderate gastrointestinal adverse effects, with nausea in roughly one-third of patients, and an increased risk of biliary disease, including gallstones. Pancreatic and thyroid cancers were too uncommon for definitive conclusions in that review. The thyroid boxed warning rests on rodent findings; a corresponding human cancer risk remains unconfirmed.

SUSTAIN-6 studied people with type 2 diabetes at high cardiovascular risk. It found fewer events in the cardiovascular composite, alongside more diabetic-retinopathy complications. The eye concern was particularly relevant with existing damage and rapidly improving blood sugar.

Community discussions describe less hunger, fewer cravings and earlier fullness, as well as nausea, constipation, diarrhea, reflux, sulfur-smelling burps, tiredness and occasional hair shedding. These anecdotal accounts are not clinical evidence. The product used and other changes in a person's life are often unclear.

Compounded medicines are not FDA-approved. A pharmacy-mixed or unchecked preparation does not automatically share the approved finished product's quality or trial evidence. Treatment decisions require a clinician who can weigh the specific product, indication, medical history and risks.